Minerva Neurosciences Announces Proposed Public Offering of Common Stock
WALTHAM, Mass., 2016-06-13 22:01 CEST (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced its intention to offer and sell shares of its common stock in an underwritten public offering pursuant to an existing shelf registration statement. All of the shares in the proposed offering are to be sold by Minerva. The offering is subject to market conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the offering.
Jefferies LLC is acting as the sole book-running manager for the offering. JMP Securities LLC is acting as lead manager for the offering. Minerva intends to grant the underwriters a 30-day option to purchase additional shares of its common stock in an amount up to 15% of the shares sold in the offering, on the same terms and conditions.
Minerva intends to use the net proceeds from the offering, together with its existing cash and investments, to fund part of the continued clinical development of MIN-101, MIN-117, MIN-202 and MIN-301, and for working capital and general corporate purposes.
The securities described above are being offered pursuant to a shelf registration statement on Form S-3 (File No. 333-205764) that was filed with the United States Securities and Exchange Commission (“SEC”) on July 21, 2015 and that was declared effective by the SEC on July 27, 2015. The offering can be made only by means of a written prospectus and prospectus supplement that form a part of the registration statement. A preliminary prospectus supplement and accompanying prospectus relating to the offering has been filed with the SEC and is available on the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying prospectus may also be obtained by request at Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, 2nd Floor, New York, NY 10022, telephone: (877) 821-7388, e-mail: Prospectus_Department@Jefferies.com.
The securities described above have not been qualified under any state blue sky laws. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Minerva Neurosciences
Minerva Neurosciences, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of a portfolio of products to treat CNS diseases. Minerva’s proprietary compounds include: MIN-101, which has completed Phase IIb development for schizophrenia; MIN-202 (JNJ-42847922), which has completed Phase IIa and Phase Ib clinical trials in insomnia and MDD, respectively; MIN-117, which has completed Phase IIa development for MDD; and MIN-301, in pre-clinical development for Parkinson’s disease. Minerva’s common stock is listed on the NASDAQ Global Market under the symbol “NERV.”
Any statements in this press release about future expectations, plans and prospects for Minerva Neurosciences, Inc., including statements about Minerva’s anticipated public offering, anticipated use of proceeds and plans and prospects for Minerva and other statements containing the words “anticipate,” “believe,” “estimate,” “expect,” “intend,” “may,” “plan,” “predict,” “project,” “target,” “potential,” “will,” “would,” “could,” “should,” “continue,” and similar expressions, constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties related to market conditions and the completion of the public offering on the anticipated terms or at all, uncertainties inherent in the initiation of future clinical trials and such other factors as are set forth in the risk factors detailed in Minerva’s Quarterly Report on Form 10-Q filed with the SEC on May 3, 2016 under the heading “Risk Factors.” In addition, the forward-looking statements included in this press release represent Minerva’s views as of the date hereof. Minerva anticipates that subsequent events and developments will cause Minerva’s views to change. However, while Minerva may elect to update these forward-looking statements at some point in the future, Minerva specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Minerva’s views as of any date subsequent to the date hereof.
William B. Boni
VP, Investor Relations/
Minerva Neurosciences, Inc.
Om Nasdaq GlobeNewswire
One Liberty Plaza - 165 Broadway
NY 10006 New York
+1 212 401 8700http://www.nasdaqomx.com
NASDAQ (NASDAQ: NDAQ) is a leading provider of trading, exchange technology, information and public company services across six continents.
Følg saker fra Nasdaq GlobeNewswire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Nasdaq GlobeNewswire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Nasdaq GlobeNewswire
3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL(TM) Test for Hodgkin's Lymphoma20.2.2018 14:00 | Pressemelding
3D Signatures Inc. / 3D Signatures Inc. Announces Positive Topline Results of Development Trial Assessing its Telo-HL(TM) Test for Hodgkin's Lymphoma . Processed and transmitted by Nasdaq Corporate Solutions. The issuer is solely responsible for the content of this announcement. TORONTO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- 3D Signatures Inc. (TSX-V:DXD) (OTCQB:TDSGF) (FSE:3D0) (the "Company" or "3DS") is pleased to announce that a preliminary third-party analysis of the trial data for Telo-HLTM, 3DS' test in development for Hodgkin's lymphoma (HL), shows that the Company's TeloViewTM platform is able to distinguish, with a high degree of statistical significance, multiple differences between a patient group that responds to standard ABVD chemotherapy, and a group that relapses or is refractory to treatment within the first 12 months. Telo-HLTM is intended to provide clinicians with the first biomarker to identify the 15% - 20% of new HL patients who will likely fail standard chemot
Cisco Leadership In Automation Continues With New Network Automation Portfolio for Service Providers20.2.2018 14:00 | Pressemelding
Company launches industry's most comprehensive closed-loop multi-vendor, multi-domain automation solution SAN JOSE, Calif., Feb. 20, 2018 (GLOBE NEWSWIRE) -- Cisco today introduced its new Cisco Crosswork Network Automation software portfolio to improve how global service providers run their large-scale networks. The solutions are designed to work together to offer greater network visibility at scale (mass awareness), data-driven insights (augmented intelligence) and outcome-based automation (proactive control). With 27 billion devices and connections1 expected to be running on service provider networks by 2021, the pressure is on for industry adoption of complete lifecycle network automation and intent-based networking to help networks predict change and react in near real time. Traditional operations staff will not be able to keep up with adding nearly 10 percent more devices every year without changing how they work. When Cisco automation is utilized, typical results include a 70 pe
Crown Bioscience Inc.: CAR T-Cell Therapy Platform20.2.2018 14:00 | Pressemelding
Bioluminescent Imaging Capabilities Accelerate Robust CAR T-Cell Therapy SAN DIEGO, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Crown Bioscience, a wholly-owned subsidiary of Crown Bioscience International (TWSE:6554) and a global drug discovery and development services company providing translational platforms to advance oncology, inflammation, cardiovascular and metabolic disease research, enhances its existing platform for chimeric antigen receptor (CAR) T-cell agent evaluation with bioluminescent imaging capabilities. CAR T-cell therapies are an exciting advent in the evolving field of immune-therapeutics. CAR T-cell agents utilize CAR T-cells that recognize tumor-associated antigens and subsequently promote tumor elimination. The remarkable efficacy of CAR T-cell compounds has led to hundreds of clinical trials with two notable successes recently approved by the FDA to treat refractory B-cell precursor acute lymphoblastic leukemia (ALL). CrownBio, a leader in the field of preclinical immuno
Standard Lithium Provides California Lithium Exploration Update20.2.2018 11:30 | Pressemelding
VANCOUVER, British Columbia, Feb. 20, 2018 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. ("Standard Lithium" or the "Company") (TSX-V:SLL) (OTCQX:STLHF) (FRA:S5L) is pleased to provide an update of the exploration program that is in full swing at the Company's California Lithium Properties. The Company and their drilling contractors have now completed six exploration boreholes across the Bristol Dry Lake Project area, and three of the exploration holes have had temporary sampling casing installed so that high quality lithium brine samples can be collected from the extensive lithium brine-bearing aquifers. The temporary PVC casing also allows for down-hole geophysics to be completed to collect additional geological and hydrogeological data. Drilling of an observation well is currently ongoing, and once completed, will allow for robust pumping tests to be performed at the Project. An additional exploration well and observation well are already permitted, and the Company is awaiting final con
Infomedia goes global with acquisition of Opoint Technology20.2.2018 10:11 | Pressemelding
COPENHAGEN, Denmark, Feb. 20, 2018 (GLOBE NEWSWIRE) -- The Copenhagen based, Nordic media intelligence company, Infomedia acquires Norwegian Opoint Technology from M-brain. The transfer includes Opoint's leading global web-crawling technology for online media, the business of web-crawling services for +70 international media monitors and key personnel in Oslo and Chennai. Continued international growth in insights, global content and social media Over the last couple of years, Infomedia had begun a journey towards becoming a Nordic player. The company invested heavily in new technology, data science, insight products and services and new partnerships. "We transformed Infomedia from a 'traditional' media monitor to becoming a full-scale media intelligence company with strong insights capabilities and leading solutions within all aspects of the media space, including print, online, broadcast and social media," says Infomedia's CEO, Thomas Vejlemand. He continues; "The acquisition marks y
SoftServe and Adjoint Deliver the Future of Blockchain in FinTech20.2.2018 07:00 | Pressemelding
New Partnership to Bring Financial Sector Unmatched Security and Scalability for Mission Critical Blockchain Applications LONDON, Feb. 20, 2018 (GLOBE NEWSWIRE) -- SoftServe, a leading digital consulting company, today announced its partnership with Adjoint, a developer of distributed ledger technology to accelerate automation through smart contracts and improve transactional privacy and security through blockchain in the financial and commodities industries. Adjoint's Uplink is an open source platform designed to enable enterprises in the financial sector, from banking and capital markets, to insurance, asset management, and commodities trading; to quickly deploy, maintain, verify and execute smart contracts globally on a private, permissioned distributed ledger. SoftServe will work with Adjoint to specifically help customers assimilate and on-board the Uplink platform effectively. SoftServe will tap into its deep technical expertise in blockchain, user experience and design, and go-t
I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.Besøk vårt presserom